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Abstract
Background: Although interferon-gamma release assays (IGRA) are promising alternatives to the tuberculin skin test,
interpretation of repeated testing results is hampered by lack of evidence on optimal cut-offs for conversions and
reversions. A logical start is to determine the within-person variability of T-cell responses during serial testing.
Methodology/Principal Findings: We performed a pilot study in India, to evaluate the short-term reproducibility of
QuantiFERON-TB Gold In Tube assay (QFT) among 14 healthcare workers (HCWs) who underwent 4 serial QFT tests on day 0,
3, 9 and 12. QFT ELISA was repeated twice on the same sets of specimens. We assessed two types of reproducibility: 1) test-
retest reproducibility (between-test variability), and 2) within-person reproducibility over time. Test-retest reproducibility:
with dichotomous test results, extremely high concordance was noticed between two tests performed on the same sets of
specimens: of the 56 samples, the test and re-test results agreed for all but 2 individuals (k=0.94). Discordance was noted in
subjects who had IFN-c values around the cut-off point, with both increases and decreases noted. With continuous IFN-c
results, re-test results tended to produce higher estimates of IFN-c than the original test. Within-person reproducibility:
when continuous IFN-c data were analyzed, the within-person reproducibility was moderate to high. While persons with
negative QFT results generally stayed negative, positive results tended to vary over time. Our data showed that increases of
more than 16% in the IFN-c levels are statistically improbable in the short-term.
Conclusions: Conservatively assuming that long-term variability might be at least twice higher than short-term, we
hypothesize that a QFT conversion requires two conditions to be met: 1) change from negative to positive result, and 2) at
least 30% increase in the baseline IFN-c response. Larger studies are needed to confirm our preliminary findings, and
determine the conversion thresholds for IGRAs.
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Introduction
In many high-income countries with low rates of tuberculosis
(TB), serial testing for latent TB infection (LTBI) is recommended
for persons at increased risk of TB exposure, such as healthcare
workers.[1] However, the conventional tuberculin skin test (TST)
has known limitations in accuracy and reliability,[2] and the
interpretation of repeated TST results is complicated because of
non-specific variations in test results (due to test related error and
biological variations over time), boosting, conversions, and
reversions.[3]
Recently, in-vitro assays for LTBI–interferon-gamma (IFN-c)
release assays (IGRAs) have been developed. IGRAs are highly
specific, especially in BCG vaccinated populations.[4] IGRAs have
characteristics that are ideal for serial testing[5]: they are more
specific than TST, can be repeated without concerns about
sensitization and boosting, and testing protocol requires fewer
visits. Unlike the TST, IGRAs do not require a baseline two-step
testing protocol.
Although IGRAs have been recommended for serial testing in
some countries,[6] there is still uncertainty regarding the
interpretation of serial IGRA test results.[5,7] Data are currently
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(reliability) of T cell responses over time (within-person variability
over time)? 2) What is a IGRA ‘‘reversion’’ and what is the clinical
significance of a IGRA reversion? 3) What is a IGRA
‘‘conversion’’ and what threshold (cut-off) should be used to
define conversion? 4) How can IGRA conversions be distinguished
from non-specific (random) variations in T cell responses over
time? 5) What is the prognosis of a IGRA conversion and will
treatment of individuals with IGRA conversions reduce their
subsequent risk of progression to active TB?
Despite the licensure of two commercial IGRAs, there are
limited data on the reproducibility of IGRAs, particularly with
regard to within-person variability of T-cell responses during serial
testing. For example, how much day to day, month to month, and
year to year variability is expected with repeated IGRA testing,
even in the absence of new exposure? If the same specimen is
tested again, how much test-retest variation is likely? Also, there
are limited data on how much IFN-c responses will increase
following new infection and how to differentiate this from changes
due to test-related error or non-specific biological variations over
time. In other words, how much variation in IFN-c level is normal
(i.e. expected ‘wobble’ or ‘noise’) with serial testing, beyond which
increases in the IFN-c levels likely indicates a genuine conversion
(i.e. new infection)? Without such data on variations in T cell
responses over time, the results of serial IGRA testing are difficult
to interpret.[5]
We performed a pilot study in India, to evaluate the short-term
reproducibility of QuantiFERON-TB Gold In Tube assay (QFT;
Cellestis Ltd, Carnegie, Australia), a whole-blood IGRA among
healthcare workers (HCWs). We assessed two types of reproduc-
ibility: 1) test-retest reproducibility (between-test variability), and 2)
within-person reproducibility over time. Using these data, we
attempted to derive cut-offs for QFT conversions.
Methods
Setting, study design and participants
Our study was done at the Mahatma Gandhi Institute of
Medical Sciences (MGIMS), Sevagram, a rural teaching hospital
in Central India. In previous cross-sectional[8] and longitudinal
studies[9] done among the health care workers (HCWs) in this
hospital, the prevalence and annual incidence of LTBI were
estimated to be 41% and 5%, respectively. Both studies showed a
fairly high degree of concordance between TST and QFT results.
We used a short-term longitudinal study design and a repeated
measures analysis to determine the variation in the QFT results
among HCWs working in high TB exposure areas of the hospital.
This strategy was used as these HCWs had a high likelihood of
LTBI and therefore would enable us to study the reproducibility of
positive QFT results. Because HCWs in India have a high risk of
TB exposure,[10] and because our prior work has demonstrated a
high rate of conversions among HCWs in India,[9] long-term
reproducibility was not considered feasible, given the high
likelihood of new infections, and the inability to distinguish
between real conversions and non-specific variations over time.
Thus, we chose to study short-term reproducibility, where all
repeat tests were performed within a 2 week period in March and
April 2007.
After written informed consent was obtained, 14 consenting
volunteers agreed to participate in the study. The study design
included collection of baseline data (such as demographics,
occupational category, BCG scar, and previous TB infection/
disease) and collection of venous blood samples at four time-points
(days 0, 3, 9 and 12). To minimize any potential circadian
variation, blood for all 4 measurements was collected at the same
time of the day (+/2 1 hour). Participants with at least one
positive QFT result were screened for active TB disease and were
referred for follow-up as necessary. The project was approved by
institutional review boards (at MGIMS hospital and McGill
University) and written informed consent was obtained from all
volunteers.
Testing protocol for the QuantiFERON-TB Gold In Tube
assay
Venous blood was drawn into three 1 mL tubes, one containing
heparin (negative control), another containing mitogen (positive
control), and a third tube coated with early secreted antigen target
6 (ESAT-6), culture filtrate protein 10 (CFP-10), and TB7.7
(Rv2654) peptides. All blood samples on a particular day were
collected within one hour of each other, and within two hours of
collection all the tubes were incubated at 37uC for exactly
24 hours. After incubation, the harvested plasma was separated by
centrifugation and stored at 2–8uC before performing ELISA.
Specimens were not frozen at 220 or 280uC. Because specimens
were not frozen, no centrifugation or thawing was done prior to
ELISA. The blood collection procedure was video-graphed for
ensuring consistency, and time logs were maintained for all of the
above procedures.
The ELISA was planned in a manner that all plasma samples
belonging to one individual were tested on the same 96 well
microtiter plate. This was done to minimize the effect of inter-plate
variation on within-person variability over time. Two ELISA runs
were planned on the same set of samples–the time interval
between the two assays was 1 week (during this interval, the
stimulated plasma specimens were stored at 2–8uC). To minimize
inter-operator and inter-laboratory variability, all assays were
done by the same operator in the same laboratory. Two ELISA
runs were aimed to determine if the QFT results from two
different microtiter plates of the same specimens were reproduc-
ible, and if the laboratory procedures in the two runs were robust.
All procedures during the ELISA runs were in accordance with the
manufacturer’s instructions. All assays met the quality control
standards and were deemed valid (there were no indeterminate
results). The cut-off value for a positive QFT test was IFN-
c$0.35 IU/mL, as per the manufacturer’s recommended thresh-
old. According to the manufacturer, the QFT ELISA cannot
accurately estimate IFN-c levels when they exceed 15 IU/mL.
Thus, values greater than 15 IU/mL should be truncated as
15 IU/mL. However, because such truncation might artificially
increase the reliability of strongly positive test results, and because
only 1 subject had IFN-c.15 IU/mL, we performed data analyses
without truncation.
Because test reproducibility is often influenced by the expertise
of the research team, we performed this study in an institution that
had considerable experience in IGRA research, as evidenced by
several prior studies,[8,9,11,12,13] and a laboratory that had
substantial expertise in serology and immune-based testing for
infectious diseases.
Statistical analysis
The analysis focused on two types of reproducibility: 1) test-
retest (between-test) variations in IGRA results (same stimulated
samples tested in two separate ELISA assays), and 2) short-term,
within-person reproducibility in IGRA results over time (same
person tested repeatedly, on separate occasions, over a period of
time).
To examine both test-retest reproducibility and within-person
reproducibility, we considered both the dichotomized test results
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continuous measure of interferon-c levels from the QFT assay
(reported as IFN-c in international units (IU) per mL).
For dichotomous measures, the number of discordant test
results (both between tests and within individuals) was too few to
allow for formal statistical tests. The Cohen k statistic for
concordance (agreement) was used.
For continuous measures, conventional approaches such as test-
retest correlation were not used as correlation measures only linear
association, not agreement of results. Therefore, the between-test
reproducibility of the QFT results from the same sample of blood
was assessed using a linear mixed effects analysis of the difference
in test and re-test results allowing for the within-person clustering
by the inclusion of random intercepts and an autoregressive
correlation structure.[14,15] For this analysis, the test and re-test
results were examined on the log-scale so as to normalize their
difference.
To assess the within-person test reproducibility of the
continuous QFT results, only data from the initial testing of the
blood samples was considered since in routine clinical or public
health practice blood will not usually be stored and re-tested at a
later date. A linear mixed effects model analysis[14,15] of the log-
QFT results allowing for correlation of measurements taken on the
same individuals by the inclusion of random intercepts and an
autoregressive correlation structure was performed. So as to be
able to perform analyses on approximately normally distributed
data, the response was taken to be the change in log-QFT results
from the first day of testing.
Results
Description of study participants
Of the 14 volunteers who participated (age range 25 to 49; 4
women and 10 men), 10 were employed in the Internal Medicine
department and 4 worked in laboratory services. Ten of the 14
HCWs were residents or clinical fellows. None of the participants
had any immunosuppressive illness, and none reported any illness
during the study period. All HCWs had BCG scars, and one HCW
had been treated for TB disease in the past. TST was not
performed on these volunteers, because of the concern that PPD
might boost subsequent T-cell IFN-c responses. Of the 14 HCWs,
only 3 had had prior TSTs and all had negative results. Each of
the 14 HCWs underwent four serial QFT assays, and therefore a
total of 56 QFT test (1464=56) results were available for within-
person reproducibility analysis. The QFT ELISA was run twice on
the same stimulated samples and therefore data on 56 test/re-test
pairs were available to assess test-retest reproducibility.
Test-retest reproducibility
Table 1 shows the initial QFT results of all 14 HCWs for each
of the 4 time points. Table 2 shows the results of the repeat test
performed on the same specimens after 1 week. In examining the
test-retest reproducibility of dichotomous test results (i.e. test
positive or negative), extremely high concordance was noticed
between two tests performed on the same sets of plasma specimens:o f
the 56 blood samples drawn from 14 individuals, the test and re-
test results agreed for all but 2 individuals (Table 3). Table 4 shows
the IFN-c responses for the two subjects with discordant test-retest
results. Overall, 96.4% of blood samples had concordant test
results, corresponding to a k statistic of 0.94. However, these
summaries do not account for the fact that 14 individual each
contributed four samples, so that the 56 test/re-test pairs are not
entirely independent.
In examining the test-retest reproducibility of continuous IFN-c
results, re-test results tended to produce higher estimates of IFN-c
than the original test (Figure 1). As with many biological measures,
the between-test variability increases with the level of IFN-c in the
sample, and so log-transformation was required to normalize the
difference in IFN-c (test–re-test) values so that appropriate limits of
agreement [16,17] could be plotted.
Agreement between the two tests was moderate: the mean
difference is 0.173 on the log scale, with limits of agreement of
Table 1. Within-person variability in initial QFT results (14 individuals tested 4 times on day 0, 3, 9 and 12)
ID# Age Sex QFT Test 1 (Day 0) QFT Test 2 (Day 3) QFT Test 3 (Day 9) QFT Test 4 (Day 12)
Overall trend
across 4 tests
IFN-c
(IU/mL) Result*
IFN-c
(IU/mL) Result*
IFN-c
(IU/mL) Result*
IFN-c
(IU/mL) Result*
1 49 M 0.60 POSITIVE 1.44 POSITIVE 0.59 POSITIVE 0.30 NEGATIVE Discordant
2 33 M 0.67 POSITIVE 0.77 POSITIVE 0.93 POSITIVE 0.78 POSITIVE Positive
3 26 M 2.37 POSITIVE 5.52 POSITIVE 4.17 POSITIVE 2.41 POSITIVE Positive
4 28 F 12.86 POSITIVE 8.44 POSITIVE 7.43 POSITIVE 5.52 POSITIVE Positive
5 27 M 1.04 POSITIVE 1.05 POSITIVE 1.09 POSITIVE 1.44 POSITIVE Positive
6 33 M 2.12 POSITIVE 3.48 POSITIVE 1.57 POSITIVE 0.94 POSITIVE Positive
7 27 F 0.01 NEGATIVE 0 NEGATIVE 0 NEGATIVE 0 NEGATIVE Negative
8 25 F 0 NEGATIVE 0 NEGATIVE 0.05 NEGATIVE 0 NEGATIVE Negative
9 28 M 0 NEGATIVE 0 NEGATIVE 0.02 NEGATIVE 0 NEGATIVE Negative
10 25 M 1.05 POSITIVE 0.46 POSITIVE 0.57 POSITIVE 0.57 POSITIVE Positive
11 26 M 25.23 POSITIVE 25.23 POSITIVE 20.23 POSITIVE 16.82 POSITIVE Positive
12 27 F 0.45 POSITIVE 0 NEGATIVE 0.02 NEGATIVE 0.02 NEGATIVE Discordant
13 29 M 10.22 POSITIVE 6.97 POSITIVE 10.15 POSITIVE 13.62 POSITIVE Positive
14 27 M 0.03 NEGATIVE 0 NEGATIVE 0 NEGATIVE 0 NEGATIVE Negative
QFT: QuantiFERON-TB Gold In TubeH; IFN-c: interferon-gamma
*The cut-off value for a positive QFT test was IFN-c$0.35 IU/mL
doi:10.1371/journal.pone.0001850.t001
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the original scale, this suggests that about 95% of the time, a
second test performed on the same blood sample will, on average,
be 2–39% higher than the first test and will typically be 19%
greater than the initial test. For example, a blood sample that
yields a test result of 0.25 IU/mL, upon re-testing, is likely to yield
a second result in the range of 0.26 to 0.35 IU/mL while a blood
sample that yields a test result of 0.30 IU/mL if re-tested may
yield a result between 0.31 and 0.42 IU/mL. Therefore, test-retest
variability was high enough to suggest that concordant test results
were likely when initial QFT values were less than 0.25 or greater
than the positive-test threshold of 0.35 IU/mL. On the other
hand, when initial test values were close to the cut-off point, repeat
testing was likely to be discordant because of test-retest variability.
Short-term within-person reproducibility
The initial testing of the samples yielded 12 individuals with
concordant test results (all positive or all negative) and two
individuals with three of the four tests concordant (Table 1). That
is, 96.4% of individuals had concordant initial test results,
corresponding to a k statistic of 0.91. As shown in Table 2, the
repeat tests of the same samples were concordant at each of the
four time points for all individuals, so that 100% of individuals had
concordant results at all four days for the blood samples that were
re-tested (perfect agreement across all four days of testing).
Over the course of the study, continuous log IFN-c results from
the initial test tended to decrease (Figure 3). The mixed model
analysis confirmed this, finding a slight but significant decrease of
26% (1.1 to 44.8%) in the QFT results on day 12 as compared to
day 0 (p=0.049). QFT results on days 3 and 9 did not differ
significantly from the first day of testing. This indicates that the test
was reliable over the short-term, but repeatability of the actual
continuous test values (rather than the dichotomous results) might
slightly decrease over an interval of two weeks or more.
Because of the potential for drift in QFT results over the
‘‘medium term,’’ a secondary analysis was undertaken on the
Table 2. Within-person variability in serially repeated (re-test) QFT results (14 individuals tested 4 times on day 0, 3, 9 and 12)
ID# Age Sex QFT Test 1 (Day 0) QFT Test 2 (Day 3) QFT Test 3 (Day 9) QFT Test 4 (Day 12)
Overall trend
across 4 tests
IFN-c
(IU/mL) Result*
IFN-c
(IU/mL) Result*
IFN-c
(IU/mL) Result*
IFN-c
(IU/mL) Result*
1 49 M 0.71 POSITIVE 2.27 POSITIVE 1.07 POSITIVE 0.49 POSITIVE Positive
2 33 M 1.1 POSITIVE 1.26 POSITIVE 1.78 POSITIVE 1.48 POSITIVE Positive
3 26 M 3.94 POSITIVE 10.19 POSITIVE 7.34 POSITIVE 4.1 POSITIVE Positive
4 28 F 23.35 POSITIVE 14.78 POSITIVE 11.04 POSITIVE 8.74 POSITIVE Positive
5 27 M 1.61 POSITIVE 1.92 POSITIVE 1.87 POSITIVE 2.54 POSITIVE Positive
6 33 M 3.12 POSITIVE 5.44 POSITIVE 2.39 POSITIVE 1.5 POSITIVE Positive
7 27 F 0.01 NEGATIVE 0.04 NEGATIVE 0 NEGATIVE 0 NEGATIVE Negative
8 25 F 0 NEGATIVE 0.01 NEGATIVE 0 NEGATIVE 0 NEGATIVE Negative
9 28 M 0.01 NEGATIVE 0 NEGATIVE 0.01 NEGATIVE 0 NEGATIVE Negative
10 25 M 0.89 POSITIVE 0.39 POSITIVE 0.45 POSITIVE 0.45 POSITIVE Positive
11 26 M 23.35 POSITIVE 23.38 POSITIVE 17.92 POSITIVE 14.45 POSITIVE Positive
12 27 F 0.19 NEGATIVE 0 NEGATIVE 0.01 NEGATIVE 0.01 NEGATIVE Negative
13 29 M 9.49 POSITIVE 6.41 POSITIVE 8.83 POSITIVE 11.13 POSITIVE Positive
14 27 M 0.18 NEGATIVE 0 NEGATIVE 0 NEGATIVE 0 NEGATIVE Negative
QFT: QuantiFERON-TB Gold In TubeH; IFN-c: interferon-gamma
*The cut-off value for a positive QFT test was IFN-c$0.35 IU/mL
doi:10.1371/journal.pone.0001850.t002
Table 3. Test-retest concordance of two QFT tests performed
on the same set of specimens (N=56 paired specimens from
14 subjects)
Re-test QFT result
Positive* Negative
First QFT assay
result
Positive* 35 1
Negative 1 19
Concordance=96.4%; k=0.94
*The cut-off value for a positive QFT test was IFN-c$0.35 IU/mL
QFT: QuantiFERON-TB Gold In TubeH; IFN-c: interferon-gamma.
doi:10.1371/journal.pone.0001850.t003
Table 4. Raw data for the two individuals with discordant
QFT results; both individuals had discordant between-test
results and discordant within-person results*
Individual A (ID# 1) Individual B (ID# 12)
IFN-c (IU/mL) IFN-c (IU/mL)
Test # (day) Test Re-test Test Re-test
1 (day 0) 0.60 0.71 0.45 0.19
2 (day 3) 1.44 2.27 0.00 0.00
3 (day 9) 0.59 1.07 0.02 0.01
4 (day 12) 0.30 0.49 0.02 0.01
*Complete QFT results for both individuals are shown in Tables 1 and 2
QFT: QuantiFERON-TB Gold In TubeH; IFN-c: interferon-gamma
doi:10.1371/journal.pone.0001850.t004
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mixed effects model with random intercepts only, as this facilitates
estimation of the intra-class correlation (ICC) statistic, calculated
as the ratio of the within-person variability to the total variability.
We first considered a model that adjusts for testing day, and no
longer observed a significant effect of day. We therefore proceeded
to fit a model without covariates which accounts for the within-
person correlation through the random intercepts. This model
yielded an estimate of the ICC of 0.92. Based on this model, we
found no significant change in QFT results over time: estimated
change between visits was a decrease of 30% (95% CI: 257.3% to
+16.0%). This suggests that an increase in QFT of more than 16%
in a short period indicates a change that is unlikely to have
occurred through random fluctuations alone and may in fact be
attributable to a genuine change in TB infection status over a short
time period.
Discussion
IGRAs are promising alternatives to the tuberculin skin test,
and their use is rapidly expanding.[4] However, little evidence is
available to guide the interpretation of repeated (serial) testing
results.[5,7] Existing studies suggest that conversions, reversions
and non-specific variations occur with IGRA serial testing, just as
they do with TST serial testing.[9,18,19,20,21] Serial testing
studies suggest that IGRAs are highly dynamic tests and T-cell
responses, especially weakly positive responses, tend to fluctuate
over time, even in the absence of specific treatment.[9,18,19,20]
There is growing evidence that IGRAs may be inherently prone to
conversions and reversions, and this dynamic characteristic raises
concerns as to whether these assays are too labile or lack in
reproducibility for serial testing.[5] Although IGRAs are often
thought of as tests that produce dichotomous (yes/no) results,
studies show that these tests are threshold dependent (i.e. depend
on the cut-off points used), and that the optimal thresholds to
distinguish new infections from non-specific variation are yet to be
defined.[9,18] Also, the need for reproducibility studies has been
articulated in several recent reviews.[4,5,7]
The results of our pilot study of short-term reproducibility
suggest the following: When QFT results are interpreted using a
dichotomous (positive/negative) approach, then test-retest and
within-person reproducibility is very high. This may be due, in
part, to the fact that most of the individuals in the study had QFT
results that were well below or well above the cut-off of IFN-c
0.35 IU/mL. Negative QFT results, for example, were almost
always zero or very close to zero. Discordance was mostly noted in
subjects who had IFN-c values around the cut-off point. This is
expected and is in line with previous studies that have shown a
high frequency of reversions among individuals with weakly
positive IGRA results (i.e. IFN-c responses close to the test cut-off
for positivity) and among individuals with an initial discordant
result with TST.[5,9,18,19,20,22] Therefore, health professionals
Figure 1. Test versus re-test QFT results expressed as IFN-c (IU/
mL). Data for each individual is plotted with different symbols, and the
line of equality is shown as the diagonal. Note that more points fall
above the line of equality than below, indicating higher IFN-c levels
upon re-testing of blood. The spread of the IFN-c results from the line of
equality increases with increasing IFN-c results, indicating that a log-
transformation was appropriate. QFT: QuantiFERON-TB Gold In TubeH;
IFN-c: interferon-gamma.
doi:10.1371/journal.pone.0001850.g001
Figure 2. Difference in QFT results (test–re-test) versus the
average of QFT test and re-test results (all on the log scale).
Separate plotting characters are used for each individual and the mean
log-difference is shown as the broken horizontal line. We note that
there tend to be more points above zero and hence the average
difference (test–re-test) lies above 0, indicating higher IFN-c results
upon re-testing of the same specimens. QFT: QuantiFERON-TB Gold In
TubeH; IFN-c: interferon-gamma.
doi:10.1371/journal.pone.0001850.g002
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IGRA results with caution, especially if the weakly positive IGRA
result is discordant with the tuberculin skin test.
When QFT results were interpreted using the continuous IFN-c
response data, the reproducibility was moderate to high. While
those with negative QFT results (i.e. values close to 0 IU/mL)
generally stay negative, positive results tend to vary over time.
While variation in strongly positive IFN-c values is unlikely to have
any clinical impact, small variations in weakly positive IFN-c
values will most likely cause discordance during serial testing.
Overall, the impact of variations around the cut-point would
depend on how frequently IFN-c values are found close to the cut-
off point. In a previous cross-sectional study of 726 HCWs in
India,[8] we found that only about 5% of the cohort has IFN-c
values between 0.25 and 0.45 IU/mL. This suggests that
borderline values around the cut-point are probably uncommon
(although this would need to be verified in all settings), and
therefore minor variations due to QFT reproducibility may not
have a serious impact on serial testing results.
One of our study aims was to generate preliminary data on how
much variation in IFN-c level is normal with serial testing and how
much increase in the IFN-c level might indicate a genuine
conversion. This is an important issue for the identification and
treatment of IGRA conversions. To identify IGRA conversions,
there must be clarity on how to define a conversion. A simplistic
definition of QFT conversion, proposed by the US Centers for
Disease Control and Prevention (CDC), is a ‘‘change from a
negative to a positive result.’’[1] This definition is easy to use from
an operational perspective, but does a relatively small increase in
IFN-c responses constitute a true conversion? What if, for
example, the IFN-c level increased from 0.34 to 0.35 IU/mL? Is
that a real conversion that warrants 9 months of isoniazid
preventive therapy? A TST increase from 9 mm to 10 mm
will usually not be considered a true conversion,[23] because
it is known that biologic and test-related variations result in
changes of ,6 mm induration in 95% of subjects.[3] Therefore,
TST increases of $6 mm are considered to represent a true
biologic phenomenon.[3] Applying the same line of reasoning, a
minor increase from 0.34 to 0.35 IU/mL may not be a
conversion; it may merely reflect non-specific IFN-c variability
over time.
Our linear mixed effects model results showed that increases of
more than 16% in the IFN-c levels are statistically improbable.
Thus an increase beyond 16% in the baseline IFN-c level may
indicate new infection (i.e. conversion). However, this estimate of
16% reflects only short-term reliability. Conservatively assuming
that long-term within-person variability might be higher than what
we found (especially since inter-plate and inter-observer variation
is also likely in routine practice), one approach would be to inflate
the expected variation to 30%, about twice what we found. With
this assumption, it may be reasonable to hypothesize that a QFT
conversion requires two conditions to be met: 1) change from
negative to positive result, and 2) at least 30% increase in the
baseline IFN-c response.
For example, if the baseline IFN-c was 0 IU/mL, and the
repeat IFN-c was 0.35 IU/mL, this would meet both conditions
for conversion. However, if, for example, the baseline IFN-c was
0.30 IU/mL, and the repeat IFN-c was 0.35 IU/mL, this would
meet the first condition but not the second, because the IFN-c did
not increase by 30%. Future studies must validate our proposed
criterion for QFT conversion, and establish the prognosis of IGRA
conversions, especially conversions that are ‘weak’ (i.e. associated
with minor increases around the cut-off value) versus conversions
that are ‘strong’ (i.e. associated with large increases in IFN-c
levels). Until then, health professionals should be cautious about
using a simplistic negative to positive definition of conversion, and
instead consider the amount of change in absolute IFN-c
responses, as well as relevant clinical information to detect and
treat conversions. To facilitate this, laboratories must report
dichotomous as well as continuous IGRA results.
Our study had limitations. As a pilot study, it provided useful
preliminary data, but the results are not definitive. Test
reproducibility determined in a research setting may not reflect
reproducibility in field settings. Because our study was done in a
TB endemic setting with potential for ongoing exposure, the
results may not necessarily reflect the reproducibility of IGRAs in
settings with low incidence of TB. In addition, our study does not
provide any data on long-term reproducibility of IGRA results.
Since most serial testing programs recommend annual TB
screening,[1] long-term IGRA reproducibility needs to be
determined in future studies. Ideally, such studies must be done
in settings where ongoing TB exposure is unlikely (to avoid
confusing real conversions with non-specific changes in T-cell
responses). Such studies must generate data on inter-plate, inter-
observer and inter-laboratory variations in IGRA results. It is also
necessary to evaluate if fresh samples produce different results than
frozen samples (because of the potential problem of evaporation of
plasma water during cold storage and thawing). Also, our study
Figure 3. Within person variability of log IFN-c responses over
4 time points (day 0, 3, 9 and 12). Separate plotting characters are
used for each individual (N=14) who underwent 4 QFT assays on days
0, 3, 9, and 12; the dashed red line indicates the cut-off for QFT test
positivity. For each individual, the IFN-c results taken on four days are
plotted on the log scale. Most individuals do not cross the positive test
result threshold. For two individuals (lines shown in bold) whose
trajectories do cross the threshold, test results are discordant. QFT:
QuantiFERON-TB Gold In TubeH; IFN-c: interferon-gamma.
doi:10.1371/journal.pone.0001850.g003
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ELISPOT-based assays may have differing reproducibility char-
acteristics.
Serial testing studies are ongoing in countries such as Canada
and the US, and should provide definitive evidence on serial
IGRA testing and reproducibility. Ongoing cohort studies,
described elsewhere,[24] should also provide useful data on the
prognosis of IGRA conversions. Lastly, because our study showed
variations in test-retest results, there is a need to explore the use of
automated ‘robotic’ systems (that perform all the ELISA steps
including pipetting of reagents, plate shaking, etc.) in reducing
such variations, and compare the performance and costs of
automated versus manual ELISA.
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